Gil Roth01.09.14
Phase I
DiaMedica completes MAD trial . . . read more
Senesco begins dosing in new cohort . . . read more
Phase II
Intercept halts NASH trial after hitting primary endpoint . . . read more
Vertex posts initial HCV data . . . read more
Phase III
Celator hits 50% enrollment in AML trial . . . read more
Approvals
AZ/BMS diabetes drug approved . . . read more
GSK cancer combo get accelerated approval . . . read more
Filings
Acasti IND cleared by FDA . . . read more
DiaMedica completes MAD trial . . . read more
Senesco begins dosing in new cohort . . . read more
Phase II
Intercept halts NASH trial after hitting primary endpoint . . . read more
Vertex posts initial HCV data . . . read more
Phase III
Celator hits 50% enrollment in AML trial . . . read more
Approvals
AZ/BMS diabetes drug approved . . . read more
GSK cancer combo get accelerated approval . . . read more
Filings
Acasti IND cleared by FDA . . . read more